Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 2
2009 1
2011 5
2012 4
2013 2
2014 2
2015 1
2016 2
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Acute myeloid leukemia unlikely related to trabectedin treatment.
Cartoafa M, Kahatt C, Soto-Matos A, Roy E, Lardelli P. Cartoafa M, et al. Among authors: lardelli p. Acta Haematol. 2011;126(4):238-9; author reply 240. doi: 10.1159/000330952. Epub 2011 Sep 24. Acta Haematol. 2011. PMID: 21952689 No abstract available.
Plitidepsin has a safe cardiac profile: a comprehensive analysis.
Soto-Matos A, Szyldergemajn S, Extremera S, Miguel-Lillo B, Alfaro V, Coronado C, Lardelli P, Roy E, Corrado CS, Kahatt C. Soto-Matos A, et al. Among authors: lardelli p. Mar Drugs. 2011;9(6):1007-1023. doi: 10.3390/md9061007. Epub 2011 Jun 9. Mar Drugs. 2011. PMID: 21747745 Free PMC article. Clinical Trial.
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
Blay JY, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, Staddon AP, Penel N, Piperno-Neumann S, Hendifar A, Lardelli P, Nieto A, Alfaro V, Chawla SP. Blay JY, et al. Among authors: lardelli p. Eur J Cancer. 2014 Apr;50(6):1137-47. doi: 10.1016/j.ejca.2014.01.012. Epub 2014 Feb 7. Eur J Cancer. 2014. PMID: 24512981 Free article. Clinical Trial.
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.
Lebedinsky C, Gómez J, Park YC, Nieto A, Soto-Matos A, Parekh T, Alfaro V, Roy E, Lardelli P, Kahatt C. Lebedinsky C, et al. Among authors: lardelli p. Cancer Chemother Pharmacol. 2011 Nov;68(5):1223-31. doi: 10.1007/s00280-011-1614-z. Epub 2011 Mar 18. Cancer Chemother Pharmacol. 2011. PMID: 21416137 Clinical Trial.
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.
Grosso F, D'Incalci M, Cartoafa M, Nieto A, Fernández-Teruel C, Alfaro V, Lardelli P, Roy E, Gómez J, Kahatt C, Soto-Matos A, Judson I. Grosso F, et al. Among authors: lardelli p. Cancer Chemother Pharmacol. 2012 Jun;69(6):1557-65. doi: 10.1007/s00280-012-1864-4. Epub 2012 Apr 7. Cancer Chemother Pharmacol. 2012. PMID: 22484722 Free PMC article.
Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Ghouadni A, Delaloge S, Lardelli P, Kahatt C, Byrski T, Blum JL, Gonçalves A, Campone M, Nieto A, Alfaro V, Cullell-Young M, Lubinski J. Ghouadni A, et al. Among authors: lardelli p. Breast. 2017 Aug;34:18-23. doi: 10.1016/j.breast.2017.04.006. Epub 2017 Apr 30. Breast. 2017. PMID: 28467918 Clinical Trial.
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.
Sessa C, Del Conte G, Christinat A, Cresta S, Perotti A, Gallerani E, Lardelli P, Kahatt C, Alfaro V, Iglesias JL, Fernández-Teruel C, Gianni L. Sessa C, et al. Among authors: lardelli p. Invest New Drugs. 2013 Oct;31(5):1236-43. doi: 10.1007/s10637-013-9942-y. Epub 2013 Mar 7. Invest New Drugs. 2013. PMID: 23467812 Clinical Trial.
18 results